How Reliable is the History of Chickenpox? Varicella Serology Among Children Up to 14 Years of Age
Overview
Authors
Affiliations
Objectives: The aim of this study was to assess the seroprevalence of antibodies to varicella-zoster virus (VZV) in children of northern Greece and to estimate the reliability of varicella history.
Methods: A serosurvey of 632 children, aged 13 months to 14 years (median 5.2 years), was conducted between April 1999 and July 2001. Serum samples were tested by enzyme-linked immunosorbent assay (ELISA) for IgG antibodies to VZV (IgG Genzyme Virotech GmbH). A history of varicella in these children was obtained from the parents of all these patients. Also, a check of state health cards of the patients was done.
Results: Two hundred and forty-eight (39%) of the children were seropositive for VZV. Two hundred and thirty (36%) of the 632 children claimed to have had previous varicella infection; 87.8% were seropositive, and 12.2% lacked antibodies to VZV. One hundred and seven of the 230 children with a history of varicella had the information about the disease confirmed, as it was reported on their state health card by a pediatrician; 10.2% were seronegative for VZV. Absence of history of varicella was reported in 402 (63.6%) of the 632 children; 88.6% of those were seronegative, and 11.4% were seropositive. The percentage of incorrect negative history ranged from 6% (13-60 months of age) to 48% (120-168 months of age).
Conclusions: A large proportion of the study group (61%), mainly below 7 years of age, is susceptible to varicella. The positive predictive value of a history of varicella is 87.8%, whereas the negative predictive value of a negative history is 11.4%, which means that there is an 88.6% probability of a negative history being correct. Varicella serology may be reasonable prior to vaccination in children >10 years old with a negative chickenpox history. However, if one excludes cost considerations, it is also reasonable to vaccinate all children, irrespective of serostatus.
Yasui Y, Mitsui T, Arima F, Uchida K, Inokuchi M, Tokumura M Hum Vaccin Immunother. 2021; 17(8):2494-2500.
PMID: 33650932 PMC: 8475580. DOI: 10.1080/21645515.2021.1890968.
Riera-Montes M, Bollaerts K, Heininger U, Hens N, Gabutti G, Gil A BMC Infect Dis. 2017; 17(1):353.
PMID: 28521810 PMC: 5437534. DOI: 10.1186/s12879-017-2445-2.
Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs.
Maple P Vaccines (Basel). 2015; 3(4):988-1003.
PMID: 26690230 PMC: 4693228. DOI: 10.3390/vaccines3040988.
Field N, Amirthalingam G, Waight P, Andrews N, Ladhani S, van Hoek A Vaccine. 2013; 32(10):1213-7.
PMID: 23871823 PMC: 3969712. DOI: 10.1016/j.vaccine.2013.06.098.
The vascular effects of infection in Pediatric Stroke (VIPS) Study.
Fullerton H, Elkind M, Barkovich A, Glaser C, Glidden D, Hills N J Child Neurol. 2011; 26(9):1101-10.
PMID: 21616922 PMC: 3397827. DOI: 10.1177/0883073811408089.